IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection

Faecal Dx in the UK now covers seven key intestinal parasite groups, adding taeniid tapeworm detection without extra cost for reference lab customers.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Expanded testing menu now detects more intestinal parasites during routine visits

WESTBROOK, Maine--(BUSINESS WIRE)-- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the expansion of its Faecal Dx™ antigen testing platform in the United Kingdom with taeniid tapeworm, including Taenia and Echinococcus species. Proven to detect up to twice as many intestinal parasite infections earlier than faecal flotation alone,¹ Faecal Dx antigen testing delivers broader parasite detection in a single test for both wellness and sick-pet care.

IDEXX Faecal Dx™ antigen testing platform menu

Since launching in 2012, more than 50 million Faecal Dx antigen tests have been run worldwide,² reflecting consistent use in practice over time. With each menu expansion, Faecal Dx has grown into a diagnostic platform with increasing clinical scope.

“This advancement reflects how we innovate at IDEXX, developing platforms that grow with our customers as care evolves,” said Mike Erickson, President and CEO of IDEXX. “By broadening the insight available through Faecal Dx, we’re making faecal testing easier to incorporate into everyday decision-making, helping veterinary teams reach more pets with greater confidence.”

Taenia and Echinococcus species are recognized by the European Scientific Counsel Companion Animal Parasites (ESCCAP) as clinically important parasites.^3,4 Due to its zoonotic risk, ESCCAP identifies Echinococcus species as one of the three key parasite groups requiring preventive control in dogs and cats.³ With this addition, Faecal Dx antigen testing now detects seven of the most clinically relevant intestinal parasite groups, including hookworm, roundworm, whipworm, flea tapeworm, taeniid tapeworms, Cystoisospora and Giardia (in select panels).

Current Faecal Dx antigen testing panels and profiles for IDEXX Reference Laboratories customers in the United Kingdom now include taeniid tapeworm detection at no additional cost.* Faecal Dx test results returning positive for taeniid tapeworms will automatically initiate a complimentary follow-up Echinococcus RealPCR test.*

For more information, please visit the Faecal Dx antigen testing web page.

*IDEXX reserves the right to modify, suspend, or discontinue the offering at its sole discretion.

References

1. Burton KW, Michael H, Drake C. The utility of coproantigen testing in screening populations. Vet Parasitol. 2025;336:110459. doi:10.1016/j.vetpar.2025.110459
2. Data on file at IDEXX Laboratories, Inc. Westbrook, Maine USA: IDEXX Faecal Dx antigen test results collected January 2012–April 2026.
3. European Scientific Counsel Companion Animal Parasites. ESCCAP guidelines: Taenia spp. June 2025. Accessed September 1, 2026. https://www.esccap.org/guidelines/gl1/
4. European Scientific Counsel Companion Animal Parasites. ESCCAP guidelines: Echinococcus spp. June 2025. Accessed September 1, 2026. https://www.esccap.org/modular-guidelines/mg1/

About IDEXX

IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500™ Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit: https://www.idexx.co.uk/en-gb/.

Forward-Looking Statement

Certain statements made in the materials on IDEXX’s website, in social media posts, or via other media or channels may constitute forward-looking statements. Forward-looking statements are not statements of historical fact and can be identified by the use of words such as “expects”, “may”, “anticipates”, “intends”, “will”, “plans”, “believes”, “estimates”, and similar expressions. These forward-looking statements reflect our current expectations as of the date they are made. They are provided for informational purposes only and do not constitute representations, warranties, or commitments of any kind. No guarantee is given that any anticipated outcome, product, feature, or timeline will be achieved or delivered. Forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied, including but not limited to changes in regulatory requirements, market conditions, technology developments, and the availability of components and raw materials. IDEXX accepts no responsibility or liability for any decision made in reliance on a forward-looking statement. Any binding commitments between IDEXX and a business partner are limited exclusively to the terms set out in the applicable written agreement between the parties. These forward-looking statements speak only as of the date made. IDEXX undertakes no obligation to publicly update or revise any forward-looking statement, except as required by applicable law. The timing of release, delivery, or availability of any product, service, feature, functionality, enhancement, or expansion referenced in any IDEXX material is subject to change at IDEXX’s discretion and may not occur as planned or at all. Purchasing decisions should be based on products, services, features, and functionalities that are currently available. No statement in this material constitutes a binding commitment to deliver any particular product, feature, or functionality.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260917879004/en/

Media Relations
media@idexx.com

Investor Relations
investorrelations@idexx.com

Source: IDEXX Laboratories, Inc.

Key Terms

faecal flotation medical

A faecal flotation is a laboratory test used in veterinary medicine to detect parasite eggs or cysts in an animal’s stool by mixing the sample with a liquid that makes lighter parasite stages float to the surface for microscopic examination. It matters to investors in animal-health, diagnostics, or biotech businesses because it is a common, low-cost diagnostic service that drives demand for veterinary clinics, testing kits, and related diagnostic platforms—similar to how a routine screening test sustains business for human diagnostics.

antigen testing medical

A diagnostic test that looks for specific proteins (antigens) from a virus or other pathogen to determine if someone is currently infected. Antigen tests work like a quick fingerprint check: they give fast, often point-of-care results but are generally less sensitive than laboratory molecular tests, so they can miss some infections. Investors care because antigen testing affects demand for medical products and services, workplace safety and operations, regulatory approvals, and public-health measures that influence economic activity.

zoonotic risk medical

Zoonotic risk is the chance that an infectious agent carried by animals will jump to humans and cause illness. It matters to investors because such jumps can trigger public-health responses, regulatory action, supply-chain disruptions, or sudden shifts in demand that affect company revenues and valuations—think of it as a wildfire risk in a forest: a spark in one place can quickly force costly containment measures across many businesses.